...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Comparative study of modified release alpha-blocker exposure in elderly patients with fractures.
【24h】

Comparative study of modified release alpha-blocker exposure in elderly patients with fractures.

机译:老年骨折患者改良释放α-受体阻滞剂暴露的比较研究。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: Standard formulation alpha-blocker use has been associated with an increased risk of hypotension-related adverse events, particularly with cardiovascular indications and on treatment initiation. We investigated the association between those fractures that are commonly due to falls and modified-release doxasozin exposure. METHODS: A case-control study using UK primary care records (the THIN database) showed that 6540 cases aged 50 years or older had a record of first fracture of the hip/femur, humerus or wrist after May 2001; 26 495 controls had no fracture and were matched on practice, year of birth and sex. Exclusions for the primary analysis were previous benign prostatic hypertrophy (BPH), lower urinary tract symptoms (LUTS) or prostate cancer, major trauma at the time of the case's fracture, or a history of falls. Conditional logistic regression estimated the association between modified-release doxasozin treatment and the occurrence of fractures. RESULTS: No increased risk of fractures was associated with current use of modified-release doxasozin, adjusted odds ratios (ORs) 0.90 (95%CI 0.68, 1.19); previous use, adjusted OR 0.92 (95%CI 0.73, 1.16) or the start of a treatment episode (
机译:目的:使用标准配方的α-受体阻滞剂会增加与低血压相关的不良事件的风险,特别是与心血管适应症和治疗开始有关。我们调查了那些通常由于跌倒而导致的骨折与释放多沙唑嗪的暴露之间的关联。方法:一项使用英国初级保健记录(THIN数据库)的病例对照研究表明,年龄在50岁或以上的6540例患者在2001年5月后有髋/股骨,肱骨或腕部首次骨折的记录。 26 495名对照没有骨折,并且在实践,出生年份和性别上相匹配。对于主要分析的排除是先前的良性前列腺肥大(BPH),下尿路症状(LUTS)或前列腺癌,病例骨折时的重大创伤或跌倒史。条件Logistic回归估计了改良释放的多沙唑嗪治疗与骨折发生之间的关联。结果:目前使用调释多沙唑嗪,调整后的优势比(OR)为0.90(95%CI 0.68,1.19)并没有增加骨折风险。先前的使用,调整后的OR为0.92(95%CI 0.73,1.16)或治疗发作的开始(

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号